Genmab A/S Sponsored ADR $GMAB Shares Sold by Brandywine Global Investment Management LLC

Brandywine Global Investment Management LLC lowered its stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB) by 27.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,031,464 shares of the company’s stock after selling 381,371 shares during the period. Brandywine Global Investment Management LLC owned about 0.16% of Genmab A/S worth $31,769,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the stock. Alliancebernstein L.P. raised its position in Genmab A/S by 2.7% in the 3rd quarter. Alliancebernstein L.P. now owns 10,953,913 shares of the company’s stock valued at $335,957,000 after purchasing an additional 291,538 shares in the last quarter. Orbis Allan Gray Ltd raised its position in Genmab A/S by 38.7% in the 2nd quarter. Orbis Allan Gray Ltd now owns 7,920,400 shares of the company’s stock valued at $163,635,000 after purchasing an additional 2,209,659 shares in the last quarter. Paradigm Biocapital Advisors LP acquired a new stake in Genmab A/S in the 3rd quarter valued at about $117,063,000. Arrowstreet Capital Limited Partnership raised its position in Genmab A/S by 5.5% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,643,139 shares of the company’s stock valued at $111,735,000 after purchasing an additional 188,761 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its position in Genmab A/S by 19.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,333,303 shares of the company’s stock valued at $41,066,000 after purchasing an additional 214,674 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on GMAB. Truist Financial started coverage on Genmab A/S in a research report on Wednesday, May 27th. They issued a “buy” rating and a $40.00 price target on the stock. Morgan Stanley started coverage on Genmab A/S in a report on Monday, February 16th. They issued an “equal weight” rating and a $34.00 price objective on the stock. Guggenheim dropped their price objective on Genmab A/S from $45.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, February 23rd. Wells Fargo & Company started coverage on Genmab A/S in a report on Monday, March 2nd. They issued an “overweight” rating and a $40.00 price objective on the stock. Finally, The Goldman Sachs Group upgraded Genmab A/S from a “neutral” rating to a “buy” rating in a report on Wednesday, April 22nd. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $37.93.

Genmab A/S Trading Down 1.4%

GMAB opened at $24.80 on Tuesday. The business’s 50-day simple moving average is $26.88 and its 200-day simple moving average is $29.38. The company has a market cap of $15.46 billion, a P/E ratio of 18.79, a PEG ratio of 1.49 and a beta of 0.85. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.17 and a current ratio of 2.18. Genmab A/S Sponsored ADR has a one year low of $20.23 and a one year high of $35.43.

Genmab A/S Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.